Brief: Venus Remedies Gets Marketing Approval For Carboplatin In Uzbekistan And Docetaxel And Irinotecan In Palestine
Feb 22 (Reuters) - Venus Remedies Ltd VENR.NS :
* GETS MARKETING APPROVAL FOR CANCER DRUGS FROM UZBEKISTAN,
PALESTINE
* TO LAUNCH THESE DRUGS IN TWO COUNTRIES IN NEXT FINANCIAL
YEAR
* GOT MARKETING APPROVAL FOR CARBOPLATIN IN UZBEKISTAN AND
DOCETAXEL AND IRINOTECAN IN PALESTINE
Source text for Eikon: ID:nBSE9tFD06
Further company coverage: VENR.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Venus Remedies
See all newsBrief: Venus Remedies Sept-Quarter Consol Net Profit 256.5 Million Rupees
Brief: Venus Remedies Secured Five Marketing Authorisations Across Kazakhstan, Peru, Kuwait And Argentina
India's Venus Remedies rises after quarterly profit more than doubles
Brief: Venus Remedies June-Quarter Consol Net Profit 229.7 Million Rupees
India raises price cap on cancer drugs to tackle shortage